# Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

> **NCT03960788** · EARLY_PHASE1 · UNKNOWN · sponsor: **University of Cincinnati** · enrollment: 50 (estimated)

## Conditions studied

- Cancer of the Prostate
- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Gadoxetate Sodium

## Key facts

- **NCT ID:** NCT03960788
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-02
- **Primary completion:** 2020-01-02
- **Final completion:** 2021-01-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960788, "Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03960788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*